BioLine RX Ltd (BLRX)

16.7
-0.3(-1.76%)
  • Volume:
    105,306
  • Bid/Ask:
    16.6/16.8
  • Day's Range:
    16.6 - 17.3

BLRX Overview

Prev. Close
17
Day's Range
16.6-17.3
Revenue
-
Open
16.6
52 wk Range
15.7-57.9
EPS
-0.033
Volume
105,306
Market Cap
159.66M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
1,071,655
P/E Ratio
-1.42
Beta
1.54
1-Year Change
-69.02%
Shares Outstanding
922,867,375
Next Earnings Date
Mar 16, 2023
What is your sentiment on BioLine RX?
or
Market is currently closed. Voting is open during market hours.

BioLine RX Ltd News

BioLine RX Ltd Analysis

BioLine RX Ltd Company Profile

BioLine RX Ltd Company Profile

Employees
38
Market
Israel
  • Type:Equity
  • Market:Israel
  • ISIN:IL0011015182
  • S/N:1101518

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Read More

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellStrong SellSellStrong Sell
Technical IndicatorsNeutralSellBuySellStrong Sell
SummaryNeutralSellNeutralSellStrong Sell